BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Why has the market become so unforgiving of AI earnings?
| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 57.44 -1.07 (1.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.51 | 52 Week High | $108.96 | |||
| Open | $58.66 | 52 Week Low | $62.12 | |||
| Day High | $59.51 | P/E | N/A | |||
| Day Low | $57.17 | EPS | $-1.27 | |||
| Volume | 3,132,661 | |||||
